Epix lands drug-discovery partner

Article

Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry

Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry laboratories owned by NeoGenesis that enable the rapid screening of compounds that could be used to form new products. Epix hopes the deal will enable it to find new advanced MRI contrast agents.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.